Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with MPSIIIA.
This study is a pioneering clinical trial for Sanfilippo A syndrome, also known as MPSIIIA, a rare and serious genetic condition. It's a 'first-in-human' study, meaning it's the very first time this new treatment is undergoing testing in people. Researchers are giving a special gene therapy, which involves a modified virus delivering a healthy gene into the brain. The main goals are to find out if this treatment is safe and tolerable for patients. They will also look for early signs of whether it could be effective in improving the condition. This study is conducted in two phases, focusing on how patients react to the treatment and its potential benefits.
At a glance
What is this study about?
This study is looking into a new way to treat Sanfilippo A syndrome, also known as MPSIIIA. This is a very serious genetic condition where the body can't break down certain sugar molecules, leading to problems in the brain and other parts of the body. The new treatment is a type of 'gene therapy'. This means scientists are trying to put a healthy copy of a gene into the cells that are causing the problem. They use a special, harmless virus to carry this healthy gene into the brain.
The main idea behind this treatment is to help the body make a missing enzyme called sulfamidase. This enzyme is needed to break down those problematic sugar molecules. By giving the body the instructions to make this enzyme, researchers hope to stop or slow down the damage to the brain and improve the health of children with Sanfilippo A syndrome.
This is an early-stage study, meaning it's one of the first times this treatment is being used in people. The main focus is to check if the treatment is safe and if people can tolerate it well. They will also look for early signs that the treatment might be working.
Key takeaways
- This study tests a new gene therapy for Sanfilippo A syndrome (MPSIIIA).
- It's the first time this treatment is being given to humans.
- The main goals are to check for safety and early signs of effectiveness.
- The treatment involves delivering a healthy gene directly to the brain.
- Many tests will be done to monitor health and development.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
This study is open to both boys and girls of any age who have been diagnosed with Sanfilippo A syndrome (MPSIIIA). The medical team running the study will carefully review each potential participant's health records to ensure they meet all other necessary health requirements for taking part.
It's important to understand that even if someone has Sanfilippo A syndrome, there might be specific health reasons why they couldn't join the study. These decisions are made to ensure the safety and well-being of all participants. The study doctors will discuss all these details with families who are interested.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Do you or your child have a confirmed diagnosis of Sanfilippo A syndrome (MPSIIIA)?
- Are you considering a new, experimental gene therapy approach?
- Are you prepared for regular hospital visits and various medical tests?
- Are you comfortable with the experimental nature of a 'first-in-human' study?
What does participation involve?
Taking part in this study would involve several visits to the clinic or hospital. During these visits, the medical team will carry out various checks and tests. These will include full physical examinations, blood and urine tests, and checks of your vital signs like heart rate and blood pressure. You would also have heart recordings (ECG) and scans of your brain, such as an MRI, and liver ultrasounds to understand how you are responding to the treatment.
Researchers will also be closely monitoring for any side effects and how your body's immune system reacts to the new gene therapy. They will collect samples to measure the levels of the missing enzyme and the problematic sugar molecules. For children, there will be special tests to look at their development, memory, behaviour, and sleep patterns. The total duration of participation and the frequency of visits would be explained in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is Sanfilippo A syndrome (MPSIIIA)?
It's a serious genetic condition where the body can't properly break down certain sugar molecules, leading to problems, especially in the brain.
What is gene therapy?
Gene therapy is a treatment that aims to correct a problem by giving the body a healthy copy of a gene that is missing or not working properly.
What does 'intracerebroventricular administration' mean?
This means the treatment is delivered directly into the fluid-filled spaces within the brain.
What are the main goals of this study?
The main goals are to find out if this new gene therapy is safe, can be tolerated by patients, and if it shows early signs of helping with Sanfilippo A syndrome.
Is this the first time this treatment has been used?
Yes, this is a 'first-in-human' study, meaning it's the first time this specific gene therapy is being tested in people.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.